In diseases, such as Alzheimer's, associated with extensive reduction in pre-synaptic cholinergic activity' the status of cholinergic muscarinic and nicotinic receptors is still uncertain. Most investigations of the muscarinic receptor indicate that binding is unchanged in Alzheimer's disease although reduced total antagonist binding, selective reductions in the M2 site and moderate reductions in both Ml and M2 sites have variously been reported.26 With respect to nicotinic sites, previous measurements of a-bungarotoxin binding in Alzheimer's disease7'8 can be questioned on the basis of a dissociation between the nicotinic receptor and toxin binding in the CNS.9 Recent evidence of a close anatomical correlation between the non-muscarinic binding of acetylcholine and high affinity nicotine binding in the brain'0 suggests that nicotine (as opposed to a a-bungarotoxin) can be employed to detect cerebral nicotinic receptors. In one previous investigation of Alzheimer's disease4 nicotine binding was reported to be de-
receptor function may be abnormal in Alzheimer's disease is the extensive loss of an endogenous compound, detected for the first time in human brain, which inhibits normal nicotinic binding. Both receptor binding and the inhibitor are also substantially decreased with increasing age in the normal hippocampus.
In diseases, such as Alzheimer's, associated with extensive reduction in pre-synaptic cholinergic activity' the status of cholinergic muscarinic and nicotinic receptors is still uncertain. Most investigations of the muscarinic receptor indicate that binding is unchanged in Alzheimer's disease although reduced total antagonist binding, selective reductions in the M2 site and moderate reductions in both Ml and M2 sites have variously been reported.26 With respect to nicotinic sites, previous measurements of a-bungarotoxin binding in Alzheimer's disease7'8 can be questioned on the basis of a dissociation between the nicotinic receptor and toxin binding in the CNS. 9 Recent evidence of a close anatomical correlation between the non-muscarinic binding of acetylcholine and high affinity nicotine binding in the brain'0 suggests that nicotine (as opposed to a a-bungarotoxin) can be employed to detect cerebral nicotinic receptors. In one previous investigation of Alzheimer's disease4 nicotine binding was reported to be de-possibly reflecting the technical limitations of using unwashed membranes4 which may contain a receptor inhibitor (see below). A later report" has indicated extensive reductions of both (3H) acetylcholine and (3H) nicotine binding to washed cortical membranes in Alzheimer's disease.
In the present investigation the nicotinic receptor has been quantified using the binding of (3H) nicotine to washed hippocampal membranes, prepared postmortem from clinically and pathologically assessed patients with Alzheimer's and Parkinson's diseases, both manifesting substantial pre-synaptic cholinergic deficits. In addition to the receptor itself, the inhibition by soluble hippocampal extracts of (3H) nicotine binding to normal membranes, indicative of the presence of a "nicotine-like" endogenous ligand (other than acetylcholine),"2 was also measured.
Methods
Cases, matched for age and autopsy delay ( Choline acetyltransferase activity and protein were estimated in aliquots of the original homogenate, as previously described. 13 
Results
The mean level of (3H) nicotine binding in the hippocampus was within the range of activities previously reported for archicortical and neocortical structures in the human brain postmortem." Compared with the normal group, nicotinic receptor binding was, together with choline acetyltransferase, reduced in both Alzheimer's and Parkinson's diseases (the latter including cases with and without dementia) but not in 
